Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

@article{Krauwinkel2012PharmacokineticPO,
  title={Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.},
  author={Walter J. J. Krauwinkel and Jan Agm van Dijk and Marloes Petra Schaddelee and Charlotte Eltink and Jacqueline Meijer and Gr{\'e}gory Strabach and Sjoerd P Van Marle and Virginie M M Kerbusch and Marcel van Gelderen},
  journal={Clinical therapeutics},
  year={2012},
  volume={34 10},
  pages={
          2144-60
        }
}
BACKGROUND Mirabegron (YM178) is a β(3)-adrenoceptor agonist for the treatment of overactive bladder (OAB). As part of the clinical development program for mirabegron, 2 human volunteer studies were performed to derive detailed data on the multiple-dose pharmacokinetic (PK) properties of mirabegron. OBJECTIVE Two randomized Phase I studies were conducted to evaluate the PK properties of mirabegron, including metabolic profile and effects of age and sex, following multiple oral doses in… CONTINUE READING
BETA